Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Epstein–Barr virus (EBV)-associated malignancies are a heterogenous group of tumors that are generally relatively radiosensitive and chemosensitive in their early stages, but less amenable to conventional modality therapy in late stage or relapse. New and emerging strategies to manipulate the immune response are discussed. These strategies are used either alone or as an adjuvant therapy in combination with chemotherapy with or without monoclonal antibodies.